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The role and function of IκKα/β 
in monocyte impairment
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Following major trauma, sepsis or surgery, some patients exhibit an impaired monocyte inflammatory 
response that is characterized by a decreased response to a subsequent bacterial challenge. to 
investigate this poorly understood phenomenon, we adopted an in-vitro model of endotoxin 
tolerance utilising primary human CD14 + monocytes to focus on the effect of impairment on IκKα/β, 
a critical part of the NFκB pathway. Impaired monocytes had decreased IκKα mRNA and protein 
expression and decreased phosphorylation of the IκKα/β complex. The impaired monocyte secretome 
demonstrated a distinct cytokine/chemokine footprint from the naïve monocyte, and that TNF-α was 
the most sensitive cytokine or chemokine in this setting of impairment. Inhibition of IκKα/β with a 
novel selective inhibitor reproduced the impaired monocyte phenotype with decreased production 
of TNF-α, IL-6, IL-12p70, IL-10, GM-CSF, VEGF, MIP-1β, TNF-β, IFN-α2 and IL-7 in response to an 
LPS challenge. Surgical patients with infection also exhibited an impaired monocyte phenotype and 
had decreased SITPEC, TAK1 and MEKK gene expression, which are important for IκKα/β activation. 
our results emphasize that impaired monocyte function is, at least in part, related to dysregulated 
IκKα/β activation, and that IκKα/β is likely involved in mounting a sufficient monocyte inflammatory 
response. Future studies may wish to focus on adjuvant therapies that augment IκKα/β function to 
restore monocyte function in this clinically important problem.
Trauma, sepsis and major surgery lead to the release of danger-associated and pathogen-associated molecular 
 patterns1. In some patients, the stimulation of toll-like receptors (TLR) may contribute to an excessive inflam-
matory response and multiple organ  failure2,3. Such a major physiological insult can also lead to impaired or 
defective innate immune  responses5. The improvements in the management of critically ill patients has increased 
the number of patients surviving the early pro-inflammatory phase, however many patients still die with associ-
ated immunosuppression. This form of immune dysfunction has a variable time of onset and impairs the host’s 
ability to mount a secondary inflammatory response, resulting in failed pathogen clearance and often with 
overwhelming  infection2,6. On a cellular level, impaired monocyte function has been highly predictive of sec-
ondary infection and mortality following major trauma. This defect overlaps the frequently described endotoxin 
tolerance, characterized by decreased TNF-α production in response to lipopolysaccharide (LPS) or decreased 
monocyte HLA-DR expression.
The blunted immune response that occurs as a result of this phenomenon is in part attributed to negative 
regulation of signalling pathways such as that of Nuclear Factor Kappa-B (NFκB). A study of patients with sepsis 
has recently demonstrated decreased NFκB activation in response to  LPS7. Suppression of NFκB activation can 
occur at various levels of signalling; from changes in toll-like receptor expression, MyD88 and TNF-associated 
receptor factor (TRAF) adaptor proteins, to dysregulation of the subunits of the canonical and non-canonical 
NFκB pathway itself.
Circulating antigen-presenting monocytes allow peptides derived from antigens, such as LPS, to be processed 
in vesicles and externalized through major histocompatibility complexes (MHC) class II glycoproteins. Human 
leukocyte antigen (HLA)-DR is the most prominent of the MHC II proteins, which binds to T-cell receptors on 
T-cells8. The expression and ability to display cell surface HLA-DR is downregulated during a “reprogramming” in 
response to pathological immune environments, and this immunoparalysis reflects a decreased ability to engage 
immune effector cells to induce functional immune  responses9. Therefore, decreased monocyte HLA-DR has 
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been accepted as a reliable and reproducible marker in patients with sepsis, trauma, burns and peri-operative 
immune status, correlating with  mortality10.
A sufficient pro-inflammatory cytokine response relies, at least in part, on the propagation of a TLR ligand 
binding to its receptor with phosphorylation of the Inhibitor of Kappa-B Kinase (IκK)-α/β causing a conforma-
tional change which then phosphorylates IκBα. Ubiquitination and proteosomal degradation of IκBα may then 
follow, allowing the translocation of the active NFκB subunits such as RelA to the nucleus. The exact function 
and role of IκK-α and IκK-β in monocyte impairment are not fully understood.
The IκK complex contains two catalytic serine/threonine-specific subunits, IκK-α and IκK-β, along with the 
regulatory subunit IκK-γ. The two catalytic subunits are both approximately 750 amino acids in size, with similar 
structure. Although they perform distinct regulatory roles in canonical and non-canonical pathways, loss-of-
function studies indicate that both subunits are required to mount a sufficient pro-inflammatory  response11,12.
Caecal ligation and puncture (CLP) models have shown that both shock and sepsis lead to an initial phos-
phorylation of IκKα/β corresponding to the systemic inflammatory response syndrome (SIRS)13. Recent studies 
using a selective inhibitor of IκKα/β to prevent its phosphorylation resulted in decreased cytokine production and 
decreased end-organ  failure14. This type of model does not, however, reproduce the well-documented immune 
suppression that occurs in some patients, and thus the study of the function and role of IκKα/β as a potential 
target in human monocyte impairment is possibly important.
The aim of the present study was to investigate the expression and functionality of IκK-α & β in primary 
human monocytes using a model of endotoxin tolerance. Furthermore, we aimed to determine to what degree 
IκK-α/β inhibition recapitulated the phenotype of impaired monocyte function using a novel selective inhibitor 
called IκK-16.
Results
Low dose LPS exposure leads to a suppressed monocyte cytokine response and decreased 
HLA-DR expression. In order to study the molecular mechanisms underpinning monocyte impairment, 
we adopted the approach of isolating CD14 monocytes from whole blood of healthy volunteers and used a model 
of endotoxin tolerance similar to that of other  groups15,16. Our experience with this model regarding the purity 
and time course of the suppressed cytokine response has been previously  reported17,18. In isolated monocytes 
exposed to a low dose of LPS (10 ng/mL), there is a suppressed ability to produce TNF-α, IL-10 and IL-6 protein 
following an LPS challenge (100 ng/mL) (p < 0.05) when compared to the naïve monocyte not exposed to low 
dose LPS stimulation (Fig. 1A,B). Furthermore, impaired monocytes have decreased TNF-α gene expression as 
well as lower HLA-DR surface expression (p < 0.05) (Fig. 1C,D).
TNF-α production was the cytokine most suppressed in the impaired monocyte. The impaired 
monocyte was compared to the naïve control by profiling cytokine and chemokine differences 12 h after stimu-
lation from the 100 ng/mL LPS challenge using the multiplex assay. Analytes that were significantly suppressed 
in impaired monocyte conditions included pro-inflammatory cytokines (TNF-α, IL-1β, IL-12p70 and TNF-β), 
anti-inflammatory cytokines (IL-10, IL-1RA and IL-7), chemokines (MCP-1, IP-10 and MIP-1β) and others 
(VEGF, IFN-α2 and IL-15) (q < 0.05) (Fig. 2A). TNF-α was the most consistently different cytokine with the 
largest magnitude of suppression. Interestingly, IL-1α production was consistently increased in the impaired 
monocyte as compared to the naïve control. Cytokine and chemokine levels across conditions are shown in 
Supplementary Table 1.
endotoxin tolerance is a distinct phenomenon based on changes in cytokine and chemokine 
production. Analysis of cytokine secretion between naïve and impaired monocytes by paired PLS-DA dem-
onstrated distinct secretion patterns (Fig. 2B). The five-fold cross-validation estimated AUC for the estimated 
paired PLS-DA model using the loadings seen in Fig. 2B was 1.00, predicting the difference between naïve and 
impaired conditions in all cases.
Impaired monocytes exhibit diminished IκBα degradation and decreased IκKα/β phospho-
rylation. The cytokines that were significantly different in the impaired monocyte as compared to the naïve 
monocyte were entered into a network analysis (Metacore®, https ://porta l.geneg o.com) in order to determine 
affected signalling pathways. The signalling network with the highest prediction score was NFκB (Z-score 
323.72). This pathway included 11 seed nodes and is predicted to directly regulate the dysregulated cytokines 
of the impaired monocyte as well as HLA-DR expression (Supplemental Fig. 2). IκBα degradation in response 
to stimulation from a 100 ng/mL LPS challenge was diminished in the impaired monocyte (Fig. 3A). Given the 
evidence of decreased NFκB activation, we interrogated IκKα/β, the upstream kinase, for differences in the level 
or function of this complex. Both the gene expression and total protein of IκKα was decreased in the impaired 
monocyte compared with the naïve control (p < 0.05) (Fig. 3B,D). Levels of IκKβ were equivalent between naïve 
and impaired conditions in terms of gene expression and total protein (Fig. 3C,D). There was an increase in 
IκKα/β phosphorylation in the naïve monocyte seen maximally at 30 and 45 min following a 100 ng/mL LPS 
challenge, whereas the same response was not seen in the impaired monocyte (p < 0.05) (Fig. 3E). No differences 
in either total or phosphorylated forms of TAK-1 were seen between naïve and impaired monocytes (Fig. 4A). 
Using previously reported toll-like receptor gene expression data of the impaired  monocyte17, analysis revealed a 
complex network of signalling change between TRAF-6 and the IKK complex as demonstrated in Fig. 4B.
IκKα/β inhibition produces a tolerant-like cytokine/chemokine phenotype but does not sup-
press HLA-DR production. Given the marked differences in IκKα/β in phosphorylation between naïve 
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and impaired monocytes, we further studied the role of IκKα/β in the monocyte inflammatory response by 
using IκK-16, a novel selective inhibitor of IκKα/β. This has previously been shown to inhibit the phosphoryla-
tion of IκKα/β in animal models of shock and  sepsis13,14. Incubation of primary monocytes with IκK-16 led to 
decreased IκK/α/β phosphorylation in response to 100 ng/mL LPS challenge (Fig. 5A). IκK-16 is not toxic to 
cultured monocytes, even at high  doses17. Immunofluorescence imaging demonstrated that in naïve monocytes, 
p65 translocates to the nucleus in response to an LPS challenge (Fig. 5D). In impaired cells, however, p65 is still 
present in the cytoplasm. Cells treated with IκK-16 similarly have p65 remaining in the cytoplasm, indicat-
ing that IκK-16 treatment prevents NFκB activation. We have previously shown that IκK-16 decreases TNF-α 
and IL-10 production in a dose-related fashion, and that a concentration of 100 nM could sufficiently suppress 
production of both  cytokines17. Despite these inhibitory effects on cytokine production, there were no effects of 
IκK inhibition on HLA-DR gene expression or protein levels (Fig. 5B,C). Inhibition of IκK did not affect levels 
of IRAK-M expression (Supplementary Fig. 3). Impaired monocytes and IκK-16-treated monocytes were then 
both compared to the naïve monocyte in terms of their cytokine and chemokine profiles to determine to what 
degree suppression of IκKα/β phosphorylation contributes to the impaired phenotype (Fig. 6A). Analytes that 
were commonly suppressed in both monocyte impairment and after IκK inhibition include TNF-α, IL-6, IL-
12p70, IL-10, GM-CSF, VEGF, MIP-1β, TNF-β, IFN-α2 and IL-7 (Fig. 6B). Similarly, IL-1β levels approached a 
significant decrease in impaired and IκK inhibited conditions (p = 0.08 and p < 0.05, respectively). MCP-1 was 
the only mediator that was suppressed in monocyte impairment, but not with IκK-16 treatment. In addition to 
the analytes decreased by both IκK inhibition and impaired conditions, further analytes decreased in conditions 
Figure 1.  Low dose LPS exposure leads to suppressed cytokine production and decreased HLA-DR expression. 
Cultured primary human monocytes were treated with 10 ng/mL of LPS (impaired) or media only (naïve) for 
16 h, washed and resuspended in fresh media before challenge with 100 ng/mL of LPS. (A) Experimental design 
for endotoxin tolerance model. (B) Supernatant concentrations of TNF-α, IL-10 and IL-6 were determined 
12 h after the 100 ng/mL LPS challenge (n = 10). (C) TNF-α mRNA expression was measured at 2 h after the 
LPS challenge (n = 8). (D) Monocyte surface HLA-DR expression was measured after 16 h of naïve or impaired 
conditions by flow cytometry. A representative histogram is shown on the left, and quantitative data on the right 
(n = 7). Data shown as mean ± SE. *p < 0.05, **p < 0.01, Wilcoxon signed-rank test.
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of IκK inhibition only included IL-4, IL-8, G-CSF, EGF, IFN-γ and eotaxin production. The levels of the latter 
analytes were similar between naïve and impaired conditions. IP-10 was the only mediator that was increased 
following IκK inhibition. IFN-β levels were low across all conditions. No differences were seen between naïve 
and impaired cells but appeared higher following IκK inhibition (p = 0.051).
Patients with infection have impaired monocyte function and dysregulated IκKα expres-
sion. Surgical patients with infection were studied to determine their same monocyte function. Peripheral 
whole blood was stimulated with LPS ex-vivo (Fig. 7C) to determine their immune responsiveness, similar to 
other  groups19,20. Patients with concurrent infection had a decreased capacity for TNF-α production in response 
to a 100  ng/mL LPS challenge (p < 0.05) as seen in Fig.  7B, similar to the in-vitro model of impairment. In 
addition, they had lower baseline monocyte HLA-DR (p < 0.05) and in response to 100 ng/mL LPS stimulation 
(p < 0.01) (Fig. 7A,B). Increased circulating plasma IL-10 levels were demonstrated in patients as compared to 
healthy controls (p < 0.05), with further increases in response to 100 ng/mL LPS challenge (p < 0.01) (Fig. 7A,B). 
Levels of IκKα were elevated in patients during infection as compared with healthy volunteers (p < 0.05), whereas 
IκKβ levels were unchanged (Fig. 7D). It should be noted that studies with lengthy follow-up in patients with 
infections are uncommon. Following clinical recovery from infection, IL-10 levels returned towards that of 
healthy volunteers. Clinical details of surgical patients with infection are described in Table 1.
Figure 2.  Impaired monocytes have a distinct cytokine/chemokine signature with TNF-α production being the 
most profoundly suppressed cytokine. Cell culture supernatants were collected 12 h after the 100 ng/mL LPS 
challenge, comparing 10 ng/mL of LPS (impaired) against media only (naïve) conditions. (A) Each cytokine 
and chemokine is plotted according to its relative change from naïve to impaired conditions, where each dot 
represents a within-donor relative change. Error bars denote mean ± SE. Statistical significance is denoted by * 
for q < 0.05 and ** for q < 0.01. (B) Multilevel partial least squares discriminant analysis (PLS-DA) comparing 
the naive (green) and impaired (red) conditions. Left: Scores plot shows the individual sample values latent 
component scores. Right: Analyte contributions to defining the latent components. Data based on 10 donors.
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Patients with infection have decreased levels of toll-like receptor gene expression.
Given the impairment of monocyte function observed in patients with infection, toll-like receptor gene 
expression was studied in these patients (Fig. 8). Patients with infection had decreased levels of Signaling Inter-
mediate in Toll Pathway Evolutionarily Conserved (SITPEC), TAK1 and MEKK mRNA compared with healthy 
controls (p < 0.05). Levels of IRAK1, another central element to IκK activation, were lower than healthy controls 
(p = 0.07). At the time of infection, patients had elevated levels of monocyte IRAK-M expression, a marker of 
endotoxin tolerance, approaching statistical significance when compared to healthy controls (p = 0.06).
Discussion
We adopted a model of impaired monocyte function using isolated primary human monocytes to represent the 
decreased cellular responsiveness seen in patients who are at very high risk. The present study builds on previous 
work that was used to select the time points  studied17,18. The impaired monocytes in this model had a distinct 
profile based on cytokine and chemokine production with an AUC of 1.00, indicating that this impairment model 
profile predicted tolerant conditions in all cases. Monocytes exposed to low dose LPS had suppressed IκKα/β 
phosphorylation and decreased NFκB activation. Suppression of IκKα/β activation could explain the decreases 
in most mediators seen in the impaired monocyte, as per the loss of function experiments using IκK-16. This 
study also confirms that surgical patients with infection have suppressed host defences, specifically a decreased 
capacity for TNF-α production in response to LPS stimulation and decreased HLA-DR expression.
Many studies have demonstrated various forms of immune dysfunction following trauma, major surgery 
and sepsis. Among the most frequently observed aspects of host defence liabilities has been decreased mono-
cyte HLA-DR  expression5,21,22 and the decreased capacity for TNF-α production in response to ex-vivo LPS 
 stimulation6,19,23. Marked monocyte deactivation occurs in approximately a sixth of ill  patients5. Although the 
ideal biomarker for the “at risk” patient is not clear, impairments of these two facets of monocyte function have 
consistently predicted nosocomial infection and death in many clinical scenarios. Our findings suggest that 
TNF-α is the most sensitive cytokine in monocyte impairment. Despite many clinical reports, there are few that 
actually describe the underlying signalling mechanisms that underpin the suppressed phenotype. Recently, it 
was reported that patients undergoing major abdominal surgery who had increased p65 (NFκB) phosphoryla-
tion were at higher risk of exhibiting systemic inflammatory response syndrome (SIRS)3. Patients who develop 
infection appear to have alterations in the expression of NFκB subunits, with more p50-p50 homodimer forma-
tion, than the active p65-p50  heterodimer24,25. Van Der Poll and associates have recently reported decreased 
Figure 3.  IκKα/β signaling in the impaired monocyte. (A) Primary monocytes were cultured in either media 
only (naïve) or 10 ng/mL of LPS for 16 h, washed and resuspended in fresh media and challenged with 100 ng/
mL of LPS for 60 min. Total protein was analyzed by Western blots for IκBα and normalized to vinculin (n = 5). 
(B, C) Primary monocytes were cultured for 16 h in media only (naïve) or 10 ng/mL of LPS (impaired) and 
total protein concentrations of IκK-α & IκK-β were determined by normalizing to β-actin (n = 8 for each). (D) 
After 16 h of incubation in naïve or impaired conditions, IκK-α & IκK-β mRNA expression was measured by 
qRT-PCR normalizing to 18S (n = 7). (E, F) Monocytes were cultured in naïve or impaired conditions for 16 h, 
washed and then challenged with 100 ng/mL of LPS. Phosphorylation of IκKα/β was determined by Western 
blot and normalized to β-actin (n = 6). Original uncropped gels are available in Supplemental Material. Data is 
shown as mean ± SE. *p < 0.05, Wilcoxon signed-rank test.
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NFκB phosphorylation in response to ex-vivo monocyte LPS stimulation in patients with  sepsis7. The findings 
presented herein, showing decreased IκKα/β phosphorylation in response to an LPS challenge in the impaired 
monocyte, are consistent with this clinical study.
A high throughput study of leukocyte gene expression in trauma patients found decreased monocyte IκKβ 
 expression26. In contrast, our results show decreased IκKα mRNA and total protein levels in the impaired mono-
cyte, but equivalent IκKβ levels. Furthermore, the level of phosphorylation of these subunits was decreased in 
impaired monocytes. This may be in part due to changes upstream in the pathway that prevents the function of 
the upstream kinase of IκKα/β. We found that levels of total and phosphorylated TAK1 were similar between 
naïve and impaired conditions, in contrast to Xiong et al27. However, in their study the levels of phosphorylated 
TAK1 and activation of TAK1 is diminished in tolerant THP1 monocytes, these changes were less apparent in 
the human monocytes. In a recent report from our group we found suppressed TRAF6 gene expression in a 
similar model of  impairment17. In the current study, we undertook a pathway analysis of toll-like receptor gene 
expression in order to elucidate mechanisms of IκK dysregulation. This revealed a complex network of various 
pathways involving TAK1, NIK and MEKK1. Taken together, a TAK-1-independent mechanism resulting in 
decreased IκKα/β activation appears likely to involve an intermediate pathway between TRAF-6 and IκKα/β 
via a NIK or SITPEC/MEKK1-related mechanism. Given the observed monocyte dysfunction in patients with 
surgical infection, we interrogated the expression of genes implicated in this pathway in such patients. We found 
that the expression of SITPEC, TAK1 and MEKK1 were decreased when compared with healthy controls. IRAK-1 
levels were also lower than healthy controls, although this did not reach statistical significance (p = 0.07). These 
findings suggest that a physiological insult can lead to dysregulation of the toll-like receptor pathway, which may 
underpin the molecular mechanism resulting in supressed activation of the IκK pathway leading to impaired 
monocyte responses.
Although the TRIF pathway is affected in other models, our model showed that although TRIF-related 
mediators IP-10 and IFN-β were not significantly affected by endotoxin tolerance. In fact, both mediators were 
upregulated in IκK inhibition, suggesting compensatory TRIF activation during IκK16 treatment. Many other 
studies have shown dysregulated microRNAs and other epigenetic changes that could downregulate the NFκB 
 pathway28. We have previously reported that IκKα/β modulates the cytokine response through a miR-155-de-
pendent  mechanism17.
There is no immunoadjuvant intervention, as yet, that has consistently or reproducibly improved clinical 
mortality by reversing monocyte impairment. IFN-γ and GM-CSF have both been used in randomised controlled 
clinical trials to improve patient  outcomes29–32. Despite effectively improving monocyte function, unchanged 
Figure 4.  Upstream signalling in the impaired monocyte. (A) Monocytes were cultured in naïve or impaired 
conditions for 16 h, washed and then challenged with 100 ng/mL of LPS. TAK-1 activation was expressed as 
a ratio of phosphorylated over total TAK-1 levels, normalized to β-actin (n = 5). Original uncropped 15-well 
gels are available in Supplemental Material. For each individual sample and protein, different β-actin levels are 
presented because separate Western Blots were performed on the same samples to avoid antibody interactions. 
Data is shown as mean ± SE. *p < 0.05, Wilcoxon signed-rank test. (B) Pathway analysis of toll-like receptor 
signaling in the impaired monocyte based on gene expression profiling. The pathway analyses were generated 
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rates of death were seen. We believe that there are many aspects to the failure of these trials such as insufficient 
dosing and duration of the adjuvant as well as imperfect patient selection, given that only approximately a sixth 
of patients exhibit significant monocyte impairment. However, importantly there is an incomplete understanding 
of the underlying signalling defects involved in suppression of these important host defence parameters. Our 
group recently showed that while IFN-γ could restore TNF-α production and monocyte HLA-DR expression, a 
short exposure of IκK-16 had differing modulatory effects including decreasing TNF-α production and PD-L1 
expression while preserving IL-10 levels and CD14  expression18. The present study indicates that suppressed 
IκKα/β phosphorylation is one mechanism which contributes to a blunted cytokine and chemokine response. 
However, given the importance of monocyte HLA-DR expression in patients and the lack of influence of IκKα/β 
on HLA-DR expression, there are other signalling pathways that are likely affected. We did not study the JAK-
STAT1 pathway, but previous reports have shown a dysregulation of this pathway in endotoxin tolerance, which 
plays a role in the regulation of major histocompatibility complexes including HLA-DR33. A further relevant 
finding of our previous study is that impairment of monocyte function can lead to decreased CD14 expression, 
which has been confirmed in previous clinical  studies18,34. Therefore, the present cohort of patients with infec-
tion may have further myeloid derived suppressor cells which are heterogeneous in their CD14 expression but 
Figure 5.  IκK inhibition decreases NFκB activation but not HLA-DR expression. (A) An IκK inhibitor, 
IκK16, decreases the phosphorylation of IκKα/β as determined by Western blot. A representative blot is shown 
using β-actin as a loading control. Original uncropped 10-well gels are available in Supplemental Material. 
(B) Primary monocytes were cultured for 16 h in conditions of LPS 100 ng/mL and DMSO, or LPS 100 ng/
mL and 100 nM IκK-16. HLA-DR mRNA was determined using qRT-PCR with 18S as an internal control. (C) 
Primary monocytes were cultured for 16 h in conditions with or without 100 ng/mL of LPS and 100 nM IκK-16 
as indicated. Surface HLA-DR expression was measured by FACS (n = 6). (D) Monocytes were cultured for 
16 h, washed, resuspended and then cultured for a further 45 min in the following conditions; Unstimulated 
(media/media), Naïve (media/100 ng/mL LPS), Impaired (10 ng/mL LPS/100 ng/mL LPS), IκK-16 (100 nM 
IκK-16/100 ng/mL LPS). Representative photomicrographs for p65 (NFκB) co-localisation in each condition are 
demonstrated. Red: p65 (Texas Red), Blue: nucleus (DAPI). Images are at 40X. Scale bar is 50 μM. White arrows 
illustrate cytoplasmic or nuclear location of p65 of each condition.
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are not fully included in the analysis due to the nature of CD14 magnetic labelling technique and would be an 
interesting area for further study.
Some studies investigating animal models of sepsis have focussed on IκKα/β as a therapeutic target. In subjects 
with haemorrhagic shock and also in caecal ligation and puncture, treatment with IκK16, a novel selective inhibi-
tor, has led to improved end organ  function13,14. Our study reports the use of IκK16 with human monocytes and 
explores the mechanism of action as well as its downstream effects on cytokine and chemokine levels. Although 
this adds useful data for groups investigating this line of enquiry, we believe that the inhibitory nature of this 
potential therapy could increase the risk of subsequent infection in the clinical setting and further translational 
studies should carefully consider timing and dosing of IκK16 to prevent harmful side effects.
This study has some limitations. We believe that the process of magnetic bead isolation and culture of a 
monocyte single cell suspension causes a minimal degree of monocyte stimulation, affecting all conditions 
equally. Elevated cytokine levels are noted in the unstimulated controls, and immunofluorescence images of 
Figure 6.  Monocyte impairment has an overlapping cytokine/chemokine footprint with IκKα/β inhibition. 
Monocytes were cultured for 16 h, washed, resuspended and then cultured for a further 12 h in the following 
conditions; Unstimulated (media/media), Naïve (media/100 ng/mL LPS), Impaired (10 ng/mL LPS/100 ng/mL 
LPS), IκK-16 (100 nM IκK-16/100 ng/mL LPS) before cell culture supernatants were collected. Supernatants 
were analyzed for cytokine and chemokine concentrations by Multiplex cytokine ELISA (Supplemental Table 2) 
and the relative change compared to unstimulated conditions. Radar plots compare the effect of monocyte 
impairment (A) and the effect of IκK inhibition (B) on secretion profiles. Mediators are categorized as pro-
inflammatory (red) and anti-inflammatory (blue) cytokines, chemokines (yellow), growth factors (green) and 
other (purple). Mean log2 (expression) is plotted relative to the naïve monocyte (dotted circle) as its control, 
based on 10 donors. (C) Venn diagram demonstrating the overlapping cytokine/chemokine changes in 
monocyte impairment (red) and IκKα/β inhibition. IP-10 (bottom left) represents the only mediator increased 
during IκKα/β inhibition, and IL-1α (bottom right) represents the only mediator increased during monocyte 
impairment. *p = 0.08 between naïve and impaired conditions.
9
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12222  | https://doi.org/10.1038/s41598-020-68018-x
www.nature.com/scientificreports/
various monocyte conditions illustrates considerable p65 co-localization within the nucleus under control con-
ditions. However, exposure to 10 ng/mL of LPS does lead to impairment of numerous aspects of IκKα/β and 
NFκB signalling and is demonstrated by the distinct secretion patterns as determined by partial least squares 
discriminate analysis (PLS-DA).
Healthy subjects sampled are variable not just in their baseline level of monocyte function, but also by the 
degree to which their cells are impaired following induction of endotoxin tolerance. Our group has previously 
reported the differing but reproducible response to  endotoxin35. We have, where possible, presented paired data 
to show within-subject differences. Although studying human subjects adds a layer of experimental variability, 
it preserves the clinical variability observed in patients.
We adopted a pragmatic approach to studying in-vivo impairment by accessing surgical patients with infec-
tion with variable timing of sampling. The model of endotoxin tolerance in the present study shares some of the 
hallmark features of impaired monocyte function (most notably decreased TNF-α in response to LPS stimula-
tion) that are observed in the studied patients, as well as described in the  literature25,36,37. Interestingly, we found 
that IκKα mRNA levels were increased in patients’ monocytes at the time of infection. These findings, however, 
contrast with the decreases in IκKα gene expression observed in the in-vitro model. There are various reasons 
that could explain this difference. It is not possible to know, at the time of first sampling, how long the patient 
has been unwell. There are certain variables which cannot be controlled, including the duration of the infection, 
nutritional status, source of infection, intervention, length of time in hospital and time until return visit for collec-
tion of subsequent sample(s). Such important factors should be considered when comparing differences in IκKα/β 
expression between patient samples and an in-vitro model. These factors are representative of clinical practice.
This heterogeneous set of patients had various sources of infection and were sampled at their index hospitali-
zation and then at their subsequent follow-up in clinic. The timing of follow up sampling is influenced, in part, 
due to variable times of clinical recovery (Table 1). The patients were studied in the setting of complex colorectal 
surgical practice, and thus 5 of the 16 patients studied had inflammatory bowel disease, with 4 of these having had 
exposure to steroids in the preceding last 4 weeks which is a confounding factor. This is, however, representative 
of clinical practice and this does show relatively consistent monocyte impairment at the time of  infection15,38–40. 
The partial recovery of elevated IL-10 and IRAK-M is suggestive that these markers of monocyte impairment 
resolve in line with clinical recovery, although this was not statistically significant. It was beyond the scope of 
this study to investigate whether impaired monocyte function is predictive of further infection and death in this 
cohort of patients, however, this correlation is well  described5,6,19,41. These patients appeared to be in symbiosis 
with their infections. These clinical observations support the in-vitro model of monocyte impairment as rep-
resentative of the suppressed response seen in patients. Future studies might profitably focus on determining 
differences in IκK phosphorylation in groups of patients with infection, including both patients who do and do 
not exhibit impaired monocyte function.
In conclusion, this report indicates that dysregulated IκKα expression and decreased IκKα/β phosphorylation 
occurs in monocyte impairment; it may be a pathological mechanism underpinning the suppressed cytokine 
and chemokine responses observed in response to a subsequent stimulus, similar to that seen in surgical patients 
Table 1.  Demographics and characteristics of patients with infection. IBD, inflammatory bowel disease; SD, 
standard deviation. *In patients that underwent follow-up sampling.
Patients
(n = 16)
Men, n (%) 9 (56)
Median age, y (± SD) 58.0 (± 13.2)
Systolic blood pressure < 90 mmHg, n (%) 1 (6.3)
Heart rate > 90/min, n (%) 3 (18.8)
Leukocyte count, cells/mL (± SD) 13, 349 (± 9, 705)
Temperature > 100.4ºF, n (%) 2 (12.5)
Respiratory rate > 20/min, n (%) 0 (0)
Source of infection, n (%)
Intra-abdominal abscess 10 (62)
Pneumonia 2 (12.5)
Pelvic abscess 2 (12.5)
Deep ischiorectal abscess 1 (6)






Median days from operation to 1st sample (min–max) 11 (0–1585)
Median days from 1st sample to follow up sample (min–max)* 60 (34–208)
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with infection. Adjunctive therapy in trauma and in sepsis targeting monocyte impairment has not yet success-
fully improved mortality, in part due to an incomplete understanding of the affected signalling mechanisms 
underpinning monocyte hyporesponsiveness. Future studies should target not just restoring activation of the 
IκKα/β-NFκB pathway to restore cytokine and chemokine production, but also other affected pathways govern-
ing more aspects of monocyte impairment.
Methods
Human subjects. The study was approved by the Institutional Review Board at the University of Louisville, 
and all methods were performed in accordance with the appropriate guidelines and regulations. Following writ-
ten informed consent in all subjects, 25 mL peripheral blood was obtained via phlebotomy (Becton Dickinson, 
Franklin Lakes, NJ). Two groups of human subjects were enrolled. The first group were healthy subjects (n = 16, 
8 men, 8 women) not taking any immunosuppressant or anti-inflammatory medications and without any acute 
or chronic illnesses with ages ranging from 19 to 80 years (mean ± SD; 38.1 ± 21.8 years). The second group of 
individuals consisted of hospitalized surgical patients (n = 16; 9 men, 7 women, aged between 31 and 81 years, 
mean ± SD; 56.2 ± 15.1 years) carefully selected by one of the senior co-authors (SG) for the fact that they were 
clinically stable and “coexisting” with a significant infection. It was her thought that these patients could display 
the phenomenon of endotoxin tolerance. Phlebotomy was performed in these individuals both during the epi-
sode of infection and well after clinical recovery. The second sample was obtained 32–204 days after the initial 
sample (median 60 days). Table 1 provides the demographics for the patients in the study.
Monocyte isolation. We used methods of monocyte isolation and development of endotoxin tolerance are 
as described in our groups previous  work17,18. Positive magnetic selection of monocytes was performed accord-
ing to the manufacturer’s protocol using Human CD14 Whole Blood Microbeads (Miltenyi Biotec, Auburn, 
CA). The purity of isolated monocytes was > 95% and validated using flow cytometry through the expression 
Figure 7.  Patients with infection have decreased HLA-DR expression and TNF-α production. Peripheral blood 
was sampled from patients during infection and after recovery, and compared to that of healthy volunteers. (A) 
Baseline unstimulated levels of TNF-α and IL-10 were determined by ELISA, with monocyte surface HLA-DR 
measured by flow cytometry. (B) Whole blood was stimulated with 100 ng/mL of LPS for 4 h and TNF-α, IL-10 
and HLA-DR were measured in the same manner. (C) Experimental design for whole blood stimulation assays. 
(D) CD14 monocytes were isolated from whole blood and IκKα and IκKβ mRNA expression was measured with 
normalization to 18S. **p < 0.01, *p < 0.05, ANOVA with post-hoc Holm–Sidak test.
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of CD14; cells were also stained with Trypan blue and manually counted and demonstrated > 95% viability. 
Monocytes were suspended in RPMI-1640 medium (Sigma Aldrich, St Louis, MO) which was supplemented 
with L-glutamine, 10% foetal bovine serum, and both an antimycotic and antibiotic (Thermo Fisher Scientific, 
Waltham, MA), incubated in a humidified atmosphere with 5% CO2 at 37 °C. All cultures were performed in 
50 mL polypropylene tubes by cell suspension at a density of 1 × 106 cells per condition.
In the endotoxin tolerance model, following 1 h (h) rest after isolation, cells were cultured for 16 h with media 
only (naïve control) or with 10 ng/mL of LPS (impaired) using E. coli (0111: B4; from Sigma Aldrich, St. Louis, 
MO). At 17 h after isolation, cells were centrifuged and re-suspended at a concentration of 0.5 × 106 per mL in 
fresh culture media. Monocytes were then treated with an LPS challenge (100 ng/mL) to measure the inflam-
matory response. RNA, protein and supernatant were collected at the selected time points and stored at − 80 °C 
(Fig. 1A). For experiments utilising IκK-16, IκK-16 or DMSO were added to cells immediately after isolation (as 
described below). After 1 h following isolation, monocytes were treated with 100 ng/mL of LPS for a further 16 h 
prior to analysis. Monocyte viability was unaffected by naïve, LPS-treated and IκK-16 treated cellular  conditions17.
RnA isolation. Cells were collected at the selected time points and stored in lysis buffer at − 80 °C until later 
analysis. Total RNA was isolated with the MirVana™ miRNA isolation kit (Thermo Fisher Scientific, Waltham, 
MA). Purity and concentration of RNA were assessed by a Nanodrop N-1000 (Agilent Biosystems, Santa Clara, 
CA). RNA samples were utilized provided they achieved the criteria of a purity of 1.8–2.2, assessed by the 
absorbance ratio at 260 nm and 280 nm (A260/A280 ratio).
Messenger RNA analysis. Gene expression was determined after complementary DNA (cDNA) was gen-
erated by reverse transcription (High-Capacity cDNA Reverse Transcription kit, Life Technologies, Foster City, 
CA). Specific primers for TNF-α, HLA-DR and IRAK-M quantification were used for qRT-PCR, with normali-
zation of data to 18S as the house-keeping gene. The StepOne-Plus RealTime-PCR-System instrument was used 
with Taqman® Universal Master Mix (Applied Biosystems®, Foster City, CA). A normalized reporter value (ΔRn) 
threshold of 0.1 was used. Fold changes were determined by the ΔΔCT calculation, by comparing the impaired 
monocyte expression with the naïve monocyte as  control42.
Pathway analysis was performed on previously published publically available gene expression data obtained 
from toll-like receptor (TLR) gene expression profiling  experiments17. In the present study, fold changes and 
p-values of toll-like receptor mRNA expression comparing impaired relative to naïve conditions were uploaded 
to Ingenuity Pathway Analysis (IPA) database software. The pathway analyses were generated through the use of 
IPA (QIAGEN Inc., https ://www.qiage nbioi nform atics .com/produ cts/ingen uity-pathw ay-analy sis)4. The find-
ings of the pathway analysis are expressed as color changes to demonstrate which gene targets were upregulated 
(red) and downregulated (green).
Figure 8.  Patients with infection have decreased toll-like receptor gene expression. Peripheral blood was 
sampled from patients during infection and after recovery, and compared to that of healthy volunteers. 
CD14 monocytes were isolated from whole blood and toll-like receptor gene expression was measured with 
normalization to 18S. *p < 0.05, ‡p = 0.07, †p = 0.06 ANOVA with post-hoc Holm–Sidak test.
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Western blot analysis. Monocytes were collected and lysed by the addition of RIPA buffer containing 
phosphatase and protease inhibitors to prevent protein degradation (Thermo Scientific, Rockford, IL), and then 
stored at − 80 °C until later analysis. Samples underwent processing using a Sonifier-250 for sonification (Bran-
son Ultrasonics, Danbury, CT) and were centrifuged for 10 min at 10,000 g. To allow equal amounts of protein 
in each well, samples were quantified using a bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, 
IL). Individual 30 µg samples were denatured in combination with 1:100 2-mercaptoethanol and 4X Bolt™ LDS 
sample buffer, then loaded into Bis–Tris Plus sodium dodecyl sulfate 4–12% gradient gels. Proteins were electro-
phoretically separated using a Bolt™ Mini Gel Tank with Bolt MES running buffer (Thermo Scientific, Waltham, 
MA) for 45 min at 180 mV. This included a protein size standard (Protein Western C Standard, Bio Rad, Hercu-
les, CA). Proteins were then finally transferred over to a nitrocellulose membrane using iBlot Gel Transfer Stacks 
(Fisher Scientific, Hampton, NH). After transfer, membranes were then blocked in 5% non-fat dried milk in 
TBS-T for 1 h and underwent incubation with either rabbit or mouse anti-human primary antibodies at room 
temperature overnight. Primary antibody concentrations were as follows; Beta-actin 1:10,000, Vinculin 1:1,000, 
IκBα 1:1,000, IκKα 1:1,000, IκKβ 1:1,000, TAK-1 1:1,000, diluted in 5% non-fat dried milk with TBS-T (Cell 
Signaling, Danvers, MA). Phospho-IκKα/β and phospho-TAK-1 were diluted at 1:1,000 concentration in 5% 
Bovine Serum Albumin (BSA) in TBS-T. TBS-T was used remove unbound antibodies before membranes were 
then incubated with HRP-conjugated goat anti-rabbit or horse anti-mouse secondary antibodies, as appropri-
ate, at a concentration of 1:1,000 at room temperature for 1 h. Membranes were washed further before protein 
bands were developed with Clarity Western ECL Substrate (Bio-Rad, Hercules, California), and captured using 
a ChemiDoc MP (Bio Rad, Hercules, CA). Densitometries of each protein were determined using ImageLab 
software (Bio Rad, Hercules, CA). For quantification, IκKα, IκKβ and phospho-IκKα/β were expressed as rela-
tive density units normalized to beta-actin as a loading control. TAK-1 activation was expressed as a ratio of 
phospho-TAK1 over total TAK-1, normalized to beta-actin. Vinculin was used as the loading control for IκBα 
quantification.
flow cytometry. Isolated monocytes from the in‑vitro model. After the PBS wash, monocyte samples 
(100,000 cells) were stained with fluorescein isothiocyanate (FITC)-labelled anti-human CD14, phycoeryth-
rin (PE)-labelled anti-HLA-DR antibodies (BD Biosciences, La Jolla, CA) in 100 µL of PBS at 4 °C for 25 min. 
Monocytes underwent centrifugation, were re-suspended and washed with Dulbecco phosphate buffered saline 
(Sigma Aldrich, St. Louis, MO), and fixed in 1% paraformaldehyde solution until later analysis.
Surface levels of cellular HLA-DR expression were analysed using a FACSCalibur instrument (Becton Dick-
inson, San Diego, CA). A total of 5,000 events were acquired at the indicated time points. Mean fluorescence 
intensity (MFI) for each labelled antibody was analysed on monocytes using Cell Quest (Becton Dickinson, San 
Diego, CA). We have previously shown that the fluorescent antibodies used do not demonstrate non-specific 
binding in this  model18.
Whole blood samples. Whole blood samples of 50  μL were stained using fluorescein isothiocyanate 
(FITC)-labelled anti-human CD14 and phycoerythrin (PE)-labelled anti-HLA-DR (BD Biosciences, La Jolla, 
CA) antibodies. After 25 min of staining at 4 °C, erythrocyte lysis was achieved with EDTA, potassium bicar-
bonate, and ammonium chloride (Sigma Chemical Co., St. Louis, MO) for 6 min. Cells were then washed with 
Dulbecco Phosphate Buffered Saline (DPBS) (Sigma Chemical Co., St. Louis, MO) and fixed in 300 μL of 1% 
paraformaldehyde. For analysis, samples were run using a LSR II flow cytometer (Becton Dickinson, San Diego, 
CA) within 48 h of venipuncture with a minimum of 20,000 events were acquired. For the gating strategy (Sup-
plemental Fig. 1), the monocyte population was selected according to forward scatter and side scatter properties, 
and by gating only on CD14 positive cells to determine HLA-DR MFI using Cell Quest (Becton Dickinson, San 
Diego, CA).
cytokine analysis. Tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6 and -10, and interferon-beta 
(IFN-β) were analysed using commercially available enzyme-linked immunosorbent cytokine assays, follow-
ing the manufacturer’s instructions, in duplicate (eBioscience, San Diego, CA). For quantification, recombinant 
human cytokines were used to determine supernatant cytokine concentrations after appropriate dilution for 
accurate measurement within the standard curve. The lower limits of cytokine detection were 2 pg/mL for IL-10, 
4 pg/mL for TNF-α, 8 pg/mL for IL-6, and 25 pg/mL for IFN-β.
For multiplex cytokine experiments, 25 µL supernatant sample was used per well in duplicate in pre-mixed 
96 well plates using magnetic beads for 29 different cytokines and chemokines as per manufacturers recom-
mendations (Milliplex Human Cytokine/Chemokine 29-Plex Magnetic Bead kit, EMD Millipore, Billerica, MA). 
Recombinant pre-mixed beads were used to create a standard curve. Quality controls 1 and 2 were used. Plates 
were run using a Luminex MAGPIX instrument (EMD Millipore, MA).
IκKα/β inhibition. IκK-16 reconstituted in DMSO from stock as per manufacturer’s instructions (Sigma 
Aldrich, St. Louis, MO), before dilution in media to a concentration 100 mM of IκK-16 (final DMSO concentra-
tion of only 0.01%). The same DMSO concentration of 0.01% was used in control conditions. We have previously 
reported dose-responses up to 1,000 nM of IκK-16 for TNF-α and IL-10 production, and that cell viability is not 
affected by IκK-16 even at high  doses17.
Analysis of samples from patients with surgical infection. Whole blood monocyte surface HLA-
DR expression and plasma cytokine levels were examined at baseline 0 h (unstimulated) and following ex-vivo 
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lipopolysaccharide (LPS) stimulation (100 ng/mL) for 4 h (Fig. 7D). Plasma samples were collected after cen-
trifugation of whole blood and stored at −80 °C until analysis. Standard individual ELISA assays were performed 
for TNF-α and IL-10 plasma protein concentrations and flow cytometric analysis performed both as previ-
ously described. The remaining monocytes were isolated by magnetic bead positive selection, and mRNA was 
extracted and analysed via qRT-PCR, to compare the ratio of normalized IκKα and IκKβ mRNA expression 
(using 18S) between patient and healthy control samples. The Toll-like receptor pathway genes TRAF-6, SIT-
PEC, NIK, TAK-1, MEKK, MyD88, IRAK-1 and IRAK-M were measured by qRT-PCR using 18S as an internal 
control.
Statistical analysis. Data are shown as mean ± S.E. Continuous paired data comparing two groups were 
analysed by Wilcoxon-signed rank test. Each donor was used as its own control. Data with multiple comparisons 
were analysed primarily by one-way repeated measures analysis of variance with Holm–Sidak test for post hoc 
analysis, or one-way analysis of variance with Holm–Sidak test for post‑hoc analysis, where appropriate. Second-
ary analysis of multiplex cytokine data was undertaken by calculating the within-subject relative change,  log2 
transformation and student t-test used to calculate q-values to preserve false discovery  rate43. A p-value of < 0.05 
was considered significant. SigmaPlot was used for statistical analysis (SyStat Software, Inc., Chicago, IL) and 
PRISM 5.0 software (GraphPad) used for data presentation.
For partial least squares discriminatory analysis (PLS-DA), a multivariable analysis was conducted by model-
ling the changes in naïve and impaired conditions using R statistical software (v3.3, R Foundation for Statistical 
Computing). The partial least squares regression was undertaken by pairing samples by donor to allow latent 
component projection in a lower dimensional space. The accuracy of the model was evaluated by estimating the 
area under the curve (AUC)44.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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